Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...
CaverSTIM is an investigational device for ED post prostatectomy, implanted during surgery to restore erectile function via neuromodulation. The pilot study at Johns Hopkins University will enroll 20 ...
“The overall survival showed a 25% reduction in the risk of death. This is statistically significant,” said Thomas B. Powles, MBBS, MRCP, MD. Results of a large phase 3 study support the use of ...
In May 2024, the FDA cleared an investigational new drug application for 225Ac-FL-020. The FDA has awarded a fast track designation to 225 Ac-FL-020, an investigational PSMA-targeting radionuclide ...
In this video, recorded at the 2026 American Urological Association Annual Meeting in Washington, DC, Murilo De Almeida Luz, MD, gives an overview of the DAROL study design and key findings.
Random assignment of 1018 patients showed durable DFS improvement with durvalumab+BCG induction/maintenance vs BCG (12-to-48 month DFS: 92%–80% vs 87%–75%), while ...
Michael S. Cookson, MD, MMHC, FACS, unpacks the significance of the phase 2 ARASEC trial evaluating darolutamide in mHSPC. The novel hybrid design used in the phase 2 ARASEC trial (NCT05059236) 1 —and ...
TLX250-CDx aims to address unmet needs in ccRCC imaging, with a potential U.S. commercial launch in 2025. The FDA's initial concerns were related to sterility assurance, not the agent's safety or ...
ARASEC provides US-based, contemporary evidence supporting darolutamide plus ADT in metastatic hormone-sensitive prostate cancer, demonstrating a 71% reduction in prostate cancer-specific mortality ...
In this episode of The UroOnc Minute, host Adam B. Weiner, MD speaks with Hashim U. Ahmed, BM BCh (Oxon), about patient selection, imaging, and the future direction of focal therapy for localized ...
Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI ...
The FDA has accepted an NDA for a 3-month leuprolide mesylate formulation, with a PDUFA date set for August 29, 2025. A phase 3 trial showed 97.9% of patients achieved testosterone suppression to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results